Retatrutide has emerged as a new pharmaceutical in the fight against obesity. This groundbreaking drug, categorized as a dual GLP-1 and GIP receptor agonist, demonstrates promising results in investigations. By stimulating these receptors, Retatrutide controls cravings, {promotesinsulin secretion, and ultimately leads to significant weight loss. W